mesna

Summary

Summary: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.

Top Publications

  1. Davidson K, Devaney M, Tighe J, Rogers S, Dunlop D, Mackie M, et al. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study. Haematologica. 2003;88:1366-71 pubmed
    ..We conclude that the CODOX-M/IVAC regimen is too toxic for this group of patients and does not result in better response rates than those to currently available salvage regimens. ..
  2. Son W, Kamino K, Lee Y, Kang K. Lack of effects of sodium 2-mercaptoethane sulfonate (mesna) on Ochratoxin A induced renal tumorigenicity following life-time oral administration of Ochratoxin A in DA and Lewis rats. Toxicol Lett. 2003;142:19-27 pubmed
    Sodium 2-mercaptoethane sulfonate (Mesna) reacts with urotoxic metabolites of oxazaphosphorine drugs (e.g...
  3. Cutler M, Urquhart B, Velenosi T, Meyer zu Schwabedissen H, Dresser G, Leake B, et al. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012;52:530-42 pubmed publisher
    b>Mesna and its dimer, dimesna, are coadministered for mitigation of ifosfamide- and cisplatin-induced toxicities, respectively. Dimesna is selectively reduced to mesna in the kidney, producing its protective effects...
  4. Coriat R, Mir O, Camps S, Ropert S, Billemont B, Leconte M, et al. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. Cancer Chemother Pharmacol. 2010;65:491-5 pubmed publisher
    ..Ifosfamide+mesna was administered as 1:1 concentration for a total of 6 g/m2 of each over 5 days (i.e. 1...
  5. Murakami E, Deppenmeier U, Ragsdale S. Characterization of the intramolecular electron transfer pathway from 2-hydroxyphenazine to the heterodisulfide reductase from Methanosarcina thermophila. J Biol Chem. 2001;276:2432-9 pubmed
    ..We propose the following electron transfer pathway: HPhenH(2) to the high potential 4Fe cluster, to the low potential heme, and finally, to CoB-S-S-CoM...
  6. Sener G, Sehirli O, Cetinel S, Yeğen B, Gedik N, Ayanoğlu Dülger G. Protective effects of MESNA (2-mercaptoethane sulphonate) against acetaminophen-induced hepatorenal oxidative damage in mice. J Appl Toxicol. 2005;25:20-9 pubmed
    ..In this study we aimed to investigate the possible beneficial effect of 2-mercaptoethane sulphonate (MESNA), an antioxidant agent, against acetaminophen toxicity in mice. Balb-c mice were injected i.p...
  7. Oprea A, Bazzazi H, Kangarloo B, Wolff J. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin. Anticancer Res. 2001;21:1225-9 pubmed
    b>Mesna is a sulfohydrate administered as a supportive drug in conjunction with oxazaphosphorines to prevent bladder toxicity from metabolites...
  8. Ramondetta L, Burke T, Jhingran A, Schmandt R, Bevers M, Wolf J, et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003;90:529-36 pubmed
    The aim of this study was to determine the efficacy of cisplatin, ifosfamide, and mesna in uterine malignant mixed müllerian tumor (MMMT) and to evaluate the expression of clinically relevant molecular markers...
  9. Cohen M, Dagher R, Griebel D, Ibrahim A, Martin A, Scher N, et al. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist. 2002;7:393-400 pubmed
    ..mg daily for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors; Mesnex (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa (..

More Information

Publications62

  1. Hausheer F, Kochat H, Parker A, Ding D, Yao S, Hamilton S, et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol. 2003;52 Suppl 1:S3-15 pubmed
    ..This paper provides an overview of our approach to drug discovery and describes a novel drug, currently in clinical development, which has directly resulted from the application of this approach. ..
  2. Boven E, Westerman M, van Groeningen C, Verschraagen M, Ruijter R, Zegers I, et al. Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. Br J Cancer. 2005;92:1636-43 pubmed
    ..The recommended dose of 18.4 g m(-2) enabled safe reduction of the saline hydration schedule for cisplatin to 1000 ml. Further studies will assess whether BNP7787 offers protection against platinum-related late side effects. ..
  3. Graham D, Graupner M, Xu H, White R. Identification of coenzyme M biosynthetic 2-phosphosulfolactate phosphatase. A member of a new class of Mg(2+)-dependent acid phosphatases. Eur J Biochem. 2001;268:5176-88 pubmed
    ..The broad and disparate distribution of comB homologs suggests that the gene has been recruited frequently into new metabolic pathways...
  4. Vincenti V, Mondain M, Pasanisi E, Piazza F, Puel J, Bacciu S, et al. Cochlear effects of mesna application into the middle ear. Ann N Y Acad Sci. 1999;884:425-32 pubmed
    b>Mesna (sodium 2-mercapto-ethane sulphonate) belongs to a class of thiol compounds that produce mucolysis by disrupting the disulphide bonds of the mucus polypeptide chains...
  5. Cerny T, Leyvraz S, von Briel T, Kupfer A, Schaad R, Schmitz S, et al. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 1999;10:1087-94 pubmed
    The aim of this study was to assess the pharmacology, toxicity and activity of high-dose ifosfamide mesna +/- GM-CSF administered by a five-day continuous infusion at a total ifosfamide dose of 12-18 g/m2 in adult patients with advanced ..
  6. von Renteln D, Dulai P, Pohl H, Vassiliou M, Rosch T, Rothstein R. Endoscopic submucosal dissection with a flexible Maryland dissector: randomized comparison of mesna and saline solution for submucosal injection (with videos). Gastrointest Endosc. 2011;74:906-11 pubmed publisher
    ..To compare mesna with saline solution for ESD. Blinded, randomized, controlled, porcine study in live animals. Animal laboratory...
  7. Ypsilantis P, Tentes I, Assimakopoulos S, Kortsaris A, Scopa C, Simopoulos C. Mesna ameliorates intestinal mucosa damage after ifosfamide administration in the rabbit at a dose-related manner. J Surg Res. 2004;121:84-91 pubmed
    ..agent ifosfamide is used in the treatment of various forms of cancer in combination with the uroprotective thiol mesna (2-mercaptoethane-sulfonate)...
  8. Sener G, Sehirli O, Erkanli G, Cetinel S, Gedik N, Yeğen B. 2-Mercaptoethane sulfonate (MESNA) protects against burn-induced renal injury in rats. Burns. 2004;30:557-64 pubmed
    ..In this study we investigated the putative protective effects of 2-mercaptoethane sulfonate (MESNA) against oxidative kidney damage in rats with thermal injury...
  9. Verschraagen M, Boven E, Torun E, Hausheer F, Bast A, van der Vijgh W. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects. Biochem Pharmacol. 2004;68:493-502 pubmed
    ..from the preferential uptake of the drug in the kidneys, where BNP7787 would undergo intracellular conversion into mesna (2-mercapto ethane sulfonate), which in turn can prevent cisplatin induced toxicities...
  10. Soff G, Wang H, Cundiff D, Jiang K, Martone B, Rademaker A, et al. In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. Clin Cancer Res. 2005;11:6218-25 pubmed
    ..conducted a phase I trial of administration of a tissue plasminogen activator (tPA) with a free sulfhydryl donor (mesna). Fifteen patients with advanced solid tumors were treated...
  11. Mashiach E, Sela S, Weinstein T, Cohen H, Shasha S, Kristal B. Mesna: a novel renoprotective antioxidant in ischaemic acute renal failure. Nephrol Dial Transplant. 2001;16:542-51 pubmed
    ..After establishing the in vitro anti-oxidative potential of mesna, a sulfhydryl-containing compound, its effect on kidney function and morphology in a rat model of ischaemic acute ..
  12. Ludwig U, Riedel M, Backes M, Imhof A, Muche R, Keller F. MESNA (sodium 2-mercaptoethanesulfonate) for prevention of contrast medium-induced nephrotoxicity - controlled trial. Clin Nephrol. 2011;75:302-8 pubmed
    The purpose of this study was to examine the efficacy of sodium 2-mercaptoethanesulfonate (MESNA), a reactive oxygen scavenger, in at-risk patients given radiographic contrast agents...
  13. Crotzer D, Wolf J, Gano J, Gershenson D, Levenback C. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol. 2007;105:399-403 pubmed
    ..To evaluate the efficacy and toxicity of cisplatin and ifosfamide in the treatment of patients with malignant mixed mesodermal tumor (MMMT) of the ovary...
  14. Wolfson A, Brady M, Rocereto T, Mannel R, Lee Y, Futoran R, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107:177-85 pubmed
    ..spread had their treatments randomly assigned as either WAI or three cycles of cisplatin (C), ifosfamide (I), and mesna (M). 232 patients were enrolled, of whom 206 (WAI=105; CIM=101) were deemed eligible...
  15. Shanmugarajah D, Ding D, Huang Q, Chen X, Kochat H, Petluru P, et al. Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:857-66 pubmed publisher
    ..BNP7787 is a disulfide that undergoes thiol-disulfide exchange reactions in vivo with physiological thiols. Mesna-disulfide heteroconjugates that form as a result of these exchange reactions may play a key role in the protection ..
  16. Hausheer F, Shanmugarajah D, Leverett B, Chen X, Huang Q, Kochat H, et al. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol. 2010;65:941-51 pubmed publisher
    ..involves the inhibition of gamma-glutamyl transpeptidase (GGT) activity, mediated by BNP7787-derived mesna-disulfide heteroconjugates that contain a terminal gamma-glutamate moiety [e.g...
  17. Kabasakal L, Sehirli A, Cetinel S, Cikler E, Gedik N, Sener G. Mesna (2-mercaptoethane sulfonate) prevents ischemia/reperfusion induced renal oxidative damage in rats. Life Sci. 2004;75:2329-40 pubmed
    ..This study was designed to determine the possible protective effect of mesna (2-Mercaptoethane Sulfonate) on renal ischemia/reperfusion (I/R) injury...
  18. Buan N, Metcalf W. Methanogenesis by Methanosarcina acetivorans involves two structurally and functionally distinct classes of heterodisulfide reductase. Mol Microbiol. 2010;75:843-53 pubmed publisher
  19. Souid A, Fahey R, Dubowy R, Newton G, Bernstein M. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study. Cancer Chemother Pharmacol. 1999;44:498-504 pubmed
    ..and glutathione in whole blood, plasma, and blood cells in patients receiving high-dose alkylating agents with mesna. WR-2721 was administered (15 min intravenous infusion of 825 mg/m(2) per dose x2) to five patients with ..
  20. Kangarloo S, Gangopadhyay S, Syme R, Wolff J, Gluck S. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. Med Oncol. 2004;21:9-20 pubmed
    b>Mesna, a reactive thiol, often encounters cisplatin and carboplatin in combination protocols involving oxazaphosphorines and platinum drugs...
  21. Vieira M, Brito G, Belarmino Filho J, Macedo F, Nery E, Cunha F, et al. Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. Int J Urol. 2003;10:595-602 pubmed
    ..In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC...
  22. Schuchter L, Hensley M, Meropol N, Winer E. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895-903 pubmed
  23. Zaki E, Springate J, Taub M. Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells. Toxicol In Vitro. 2003;17:397-402 pubmed
    ..The ability of the uroprotectant medications sodium 2-mercaptoethanesulfonate (mesna) and amifostine to prevent chloroacetaldehyde- and acrolein-induced renal cell injury was also assessed...
  24. Shusterman T, Sela S, Cohen H, Kristal B, Sbeit W, Reshef R. Effect of the antioxidant Mesna (2-mercaptoethane sulfonate) on experimental colitis. Dig Dis Sci. 2003;48:1177-85 pubmed
    ..Hence, our aim was to examine the possible beneficial effect of the antioxidant 2-mercaptoethane sulfonate (Mesna) on experimental colitis...
  25. Graupner M, Xu H, White R. Identification of an archaeal 2-hydroxy acid dehydrogenase catalyzing reactions involved in coenzyme biosynthesis in methanoarchaea. J Bacteriol. 2000;182:3688-92 pubmed
    ..We conclude that the MJ1425-encoded enzyme is likely to be involved in the biosynthesis of both coenzyme M and methanopterin...
  26. Graham D, White R. Elucidation of methanogenic coenzyme biosyntheses: from spectroscopy to genomics. Nat Prod Rep. 2002;19:133-47 pubmed
    ..The literature from 1971 to September 2001 is reviewed, and 169 references are cited. ..
  27. Bastings M, van Baal I, Meijer E, Merkx M. One-step refolding and purification of disulfide-containing proteins with a C-terminal MESNA thioester. BMC Biotechnol. 2008;8:76 pubmed publisher
    ..A novel redox buffer consisting of MESNA and diMESNA showed a refolding efficiency comparable to that of GSH/GSSG and prevented loss of the protein's ..
  28. Ypsilantis P, Tentes I, Lambropoulou M, Anagnostopoulos K, Papadopoulos N, Kortsaris A, et al. Prophylaxis with mesna prevents oxidative stress induced by ischemia reperfusion in the intestine via inhibition of nuclear factor-kappaB activation. J Gastroenterol Hepatol. 2008;23:328-35 pubmed
    b>Mesna (2-mercaptoethane-sulfonate) has been shown to attenuate oxidative injury induced by ischemia reperfusion (I/R) in the kidneys, the liver, and the intestine; however, its mechanism of action has not been fully elucidated...
  29. Graupner M, Xu H, White R. Identification of the gene encoding sulfopyruvate decarboxylase, an enzyme involved in biosynthesis of coenzyme M. J Bacteriol. 2000;182:4862-7 pubmed
    ..The two subunits, designated ComD and ComE, comprise the first enzyme for the biosynthesis of coenzyme M to be described...
  30. Schwerdt G, Kirchhoff A, Freudinger R, Wollny B, Benesic A, Gekle M. Mesna or cysteine prevents chloroacetaldehyde-induced cell death of human proximal tubule cells. Pediatr Nephrol. 2007;22:798-803 pubmed
    ..During chemotherapy, 2-mercaptosulfonic acid (mesna) is used with IFO to protect the urothel from cell damage...
  31. Kanat O, Kurt E, Yalcinkaya U, Evrensel T, Manavoglu O. Comparison of uroprotective efficacy of mesna and amifostine in Cyclophosphamide- induced hemorrhagic cystitis in rats. Indian J Cancer. 2006;43:12-5 pubmed
    ..we aimed to investigate the role of amifostine in the protection of CYP-induced HC and compare its efficacy with mesna. This animal study was conducted in the Experimental Animals Breeding and Research Center of the Medical Faculty ..
  32. Verschraagen M, Boven E, Ruijter R, van der Born K, Berkhof J, Hausheer F, et al. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clin Pharmacol Ther. 2003;74:157-69 pubmed
    ..intestine, and liver, BNP7787 is believed to undergo intracellular conversion into 2-mercaptoethane sulfonate (mesna), which can locally inactivate toxic platinum species...
  33. Yildirim I, Korkmaz A, Oter S, Ozcan A, Oztas E. Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats. Cancer Chemother Pharmacol. 2004;54:469-73 pubmed
    The aim of this study was to evaluate whether combination of antioxidants and mesna may prevent cystitis induced by cyclophosphamide better than mesna alone. A total of 46 male Sprague-Dawley rats were divided into six groups...
  34. Verschraagen M, Boven E, Torun E, Erkelens C, Hausheer F, van der Vijgh W. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats. Br J Cancer. 2004;90:1654-9 pubmed
    In preclinical studies, BNP7787 (disodium 2,2'-dithio-bis-ethane sulphonate), the disulphide form of mesna, has demonstrated selective protection against cisplatin-induced nephrotoxicity due to conversion into mesna inactivating toxic ..
  35. Verschraagen M, Kedde M, Hausheer F, van der Vijgh W. The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG. Cancer Chemother Pharmacol. 2003;51:499-504 pubmed
    ..In the kidneys BNP7787 is postulated to undergo selective conversion into mesna, which can locally detoxify cisplatin...
  36. Piura B, Rabinovich A. Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. Eur J Gynaecol Oncol. 2005;26:275-8 pubmed
    To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas...
  37. Graham D, Xu H, White R. Identification of coenzyme M biosynthetic phosphosulfolactate synthase: a new family of sulfonate-biosynthesizing enzymes. J Biol Chem. 2002;277:13421-9 pubmed publisher
    ..A diverse group of microbes and plants have homologs of ComA that could have been recruited for sulfolactate or sulfolipid biosyntheses...
  38. Verschraagen M, Zwiers T, Torun E, Donker M, Reinhoud N, van der Vijgh W. Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector. J Pharm Sci. 2003;92:1040-50 pubmed
    ..precise assays are described to determine BNP7787 (disodium 2,2'-dithio-bis-ethane sulfonate) and its metabolite mesna (sodium 2-mercaptoethane sulfonate) simultaneously in plasma and tissue by micro-high-performance liquid ..
  39. Ozcan A, Korkmaz A, Oter S, Coskun O. Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats. Arch Toxicol. 2005;79:461-5 pubmed
    ..The agent most often used to prevent this side-effect is mesna (2-mercaptoethane sulfonate)...
  40. Ypsilantis P, Tentes I, Anagnostopoulos K, Kortsaris A, Simopoulos C. Mesna protects splanchnic organs from oxidative stress induced by pneumoperitoneum. Surg Endosc. 2009;23:583-9 pubmed publisher
    We investigated the potential beneficial effect of the antioxidant 2-mercaptoethane-sulfonate (mesna) against oxidative stress induced by pneumoperitoneum in splanchnic organs...
  41. Yeh J, Kim B, Peresie J. Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2-mercaptoethanesulfonate (mesna) in female rats. Am J Obstet Gynecol. 2008;198:463.e1-6; discussion 463.e6-7 pubmed publisher
    The hypothesis was that the administration of the antioxidant mesna (sodium 2-mercaptoethanesulfonate) during chemotherapy would protect ovaries against follicular damage...
  42. Boven E, Verschraagen M, Hulscher T, Erkelens C, Hausheer F, Pinedo H, et al. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer. 2002;38:1148-56 pubmed
    ..In this study, we evaluated BNP7787, mesna and amifostine for their effects on the antitumour activity of platinum compounds...
  43. Nair R, Prabhash K, Sengar M, Bakshi A, Gujral S, Gupta S, et al. The effect of short-term intensive chemotherapy on reactivation of tuberculosis. Ann Oncol. 2007;18:1243-5 pubmed
    ..None of these patients developed reactivation of tuberculosis. Cyclical chemotherapy for non-Hodgkin's lymphoma does not lead to reactivation of tuberculosis. ..
  44. Korkmaz A, Oter S, Deveci S, Goksoy C, Bilgic H. Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs. J Urol. 2001;166:1119-23 pubmed
    Hyperbaric oxygen therapy and mesna have been successfully used for hemorrhagic cystitis. We defined the protective effects of hyperbaric oxygen and mesna in further cyclophosphamide induced hemorrhagic cystitis in guinea pigs...
  45. Vlahovic A, Simic R, Djokic D, Ceran C. Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: a case report. J Pediatr Hematol Oncol. 2009;31:858-60 pubmed publisher
    ..He received 4 courses, 10 days apart. Each course consisted of 10 mg/kg/d of cyclophosphamide and 10 mg/kg/d of mesna for 4 consecutive days...
  46. Ekhart C, Rodenhuis S, Beijnen J, Huitema A. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen. Ther Drug Monit. 2009;31:95-103 pubmed publisher
  47. Meazza C, Bisogno G, Casanova M, Zanetti I, Carli M, Ferrari A. Full-dose ifosfamide can be safely administered to outpatients. Pediatr Blood Cancer. 2008;50:375-8 pubmed
    This report compares a traditional full-dose ifosfamide administration modality (24-hr hyperhydration and mesna infusion) with a simplified 9-hr hyperhydration and mesna infusion for use in outpatients...
  48. Di Vagno G, Cormio G, Loverro G, Melilli G, di Gesu G, Selvaggi L. Prolonged survival of stage IV malignant mixed Müllerian tumor of the ovary after carboplatin, mesna, ifosfamide, and cis-platin chemotherapy: case report. J Chemother. 1998;10:418-21 pubmed
    ..stage IV ovarian MMMT who achieved a surgically-documented complete response (CR) after 6 cycles of carboplatin, mesna, ifosfamide, cis-platin...
  49. Hoeppner A, Thomas F, Rueppel A, Hensel R, Blankenfeldt W, Bayer P, et al. Structure of the corrinoid:coenzyme M methyltransferase MtaA from Methanosarcina mazei. Acta Crystallogr D Biol Crystallogr. 2012;68:1549-57 pubmed publisher
  50. Hauser P, Ryan R. Expressed protein ligation using an N-terminal cysteine containing fragment generated in vivo from a pelB fusion protein. Protein Expr Purif. 2007;54:227-33 pubmed
    ..Saccharomyces cerevisiae intein and a chitin binding domain was subjected to 2-mercaptoethanesulfonic acid (MESNA) induced cleavage to generate apoE(1-111)-MESNA...
  51. Esquerdo G, Llorca C, Cervera J, Briceño H. A rare case of breast sarcoma brain metastases. J Neurooncol. 2005;72:123 pubmed
  52. Hemmings C, Fisher C. Primary omental synovial sarcoma: a case with cytogenetic confirmation. Pathology. 2004;36:208-11 pubmed
  53. Yokoyama M, Kobayashi T, Kubo Y, Kageyama Y, Kihara K. [A case of secondary malignant lymphoma of the urinary bladder]. Hinyokika Kiyo. 2006;52:285-7 pubmed
    ..The prognosis of the secondary bladder lymphoma is much poorer than that of the primary one, because of the widespread dissemination of the disease at the time of diagnosis. ..